Vitrolife AB (publ) Interim report Q1, 2025: Strong performance in EMEA

Rhea-AI Summary

Vitrolife reported Q1 2025 financial results showing mixed regional performance. Sales reached SEK 842 million, representing a 1% increase in local currencies and flat growth in SEK. Excluding discontinued business, growth was 3%. Regional performance varied significantly with EMEA showing strong growth of 8% (14% excluding discontinued business), Americas growing 9%, while APAC declined 15%.

By product category, excluding discontinued business, Consumables grew 6%, while Technologies declined 5% and Genetics increased 4%. The company's gross margin improved slightly to 57.4% from 57.1%. EBITDA decreased to SEK 257 million with a margin of 30.6%, impacted by a negative foreign exchange effect of SEK 13 million. Operating cash flow was SEK 69 million, and net income reached SEK 100 million, resulting in earnings per share of SEK 0.74.

GOTHENBURG, Sweden, April 24, 2025 /PRNewswire/ --

First quarter

• Sales of SEK 842 (841) million, an increase of 1% in local currencies and 0% in SEK. The growth in local currencies excluding discontinued business was 3%. 
• Sales per region, in local currencies was +8% in EMEA, +14% excluding discontinued business, +9% in Americas and -15% in APAC. 
• Sales per product groups, in local currencies excluding discontinued business was +6% in Consumables, -5% in Technologies and +4% in Genetics. 
• Sales per product groups, in local currencies was +3% in Consumables, -6% in Technologies and +1% in Genetics. 
• Gross margin increased to 57.4% (57.1).
• Earnings before depreciation and amortisation (EBITDA) decreased to SEK 257 (272) million, giving an EBITDA margin of 30.6% (32.4), affected by foreign exchange impact of SEK -13 (1) million. 
• Operating cash flow amounted to SEK 69 million (198). 
• Net income was SEK 100 (115) million, resulting in earnings per share of SEK 0.74 (0.85).

Gothenburg, April 24, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-04-2025 08:00 CET.

For more information, please contact: 
Helena Wennerström, acting CFO, phone: +4670 822 80 86

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/interim-report-q1--2025--strong-performance-in-emea,c4139505

The following files are available for download:

https://mb.cision.com/Main/1031/4139505/3405196.pdf

Interim report Q1, 2025

 

FAQ

What was Vitrolife's (VTRLY) revenue growth in Q1 2025?

Vitrolife's sales reached SEK 842 million, showing 1% growth in local currencies and 0% in SEK. Excluding discontinued business, growth was 3%.

How did Vitrolife's regional sales perform in Q1 2025?

EMEA showed 8% growth (14% excluding discontinued business), Americas grew 9%, while APAC declined 15% in local currencies.

What was Vitrolife's EBITDA margin in Q1 2025?

EBITDA margin was 30.6%, down from 32.4% in the previous year, affected by a negative foreign exchange impact of SEK 13 million.

How did Vitrolife's product segments perform in Q1 2025?

Excluding discontinued business, Consumables grew 6%, Technologies declined 5%, and Genetics increased 4% in local currencies.

What were Vitrolife's earnings per share in Q1 2025?

Earnings per share were SEK 0.74, down from SEK 0.85 in the previous year.